A Minnesota physician is quoted in the report saying, I know that the FDA is going to approve this, and I thought, Why are we waiting? Because retatrutide has not completed the FDA approval process, products sold online or through clinics are black market drugs and come with no guarantee of quality, purity, or dosing accuracy
Cartwright T., Endean N., and Porter A., Illness Perceptions, Coping and Quality of Life in Patients With Alopecia, British Journal of Dermatology 160, no
Semaglutide can be more expensive, but its cost may vary significantly depending on your insurance coverage, dosage, and the pharmacy used
(2025, March 31)
Key Takeaways Cagrilintide is a long-acting amylin analogue with clinical trial doses ranging from 0.3 mg to 4.5 mg weekly, while retatrutide is a triple agonist studied at 4 mg, 8 mg, and 12 mg weekly doses No published clinical trials currently exist evaluating the cagrilintide dosage with retatrutide combination, making any combined use experimental and off-label Both peptides work through different mechanismscagrilintide activates amylin receptors while retatrutide targets GIP, GLP-1, and glucagon receptorssuggesting potential complementary effects Gastrointestinal side effects (nausea, vomiting) occur in 60-80% of participants at higher doses for both compounds, raising concerns about additive effects when combined Proper dose escalation protocols spanning 8-20 weeks are critical for tolerability and adherence in peptide-based metabolic therapies Understanding Cagrilintide: Mechanism and Dosage Fundamentals What Is Cagrilintide
The strongest predictor of clinical satisfaction with at-home microinfusion in my patient population is adherence to the full sequence, not the brand of device
